Dr. Ahmed Farhan
The management of diabetes is entering a new era with the approval of Awiqli (insulin icodec)—a groundbreaking once-weekly insulin that has the potential to transform how patients and clinicians approach insulin therapy.
Approved by the U.S. Food and Drug Administration on March 26, 2026, Awiqli represents a major step forward in improving adherence, convenience, and long-term glycemic control.
What Is Awiqli (Insulin Icodec)?
Awiqli is a basal insulin analog designed for once-weekly administration, unlike traditional insulins that require daily injections.
- Generic name: Insulin icodec
- Class: Long-acting basal insulin
- Dosing frequency: Once weekly
- Indication: Diabetes mellitus (primarily type 2, under physician guidance)
Its ultra-long half-life allows for stable glucose control over an entire week with a single injection.
Why Awiqli Is a Game Changer
1. Once-Weekly Dosing Improves Adherence
Daily insulin injections are a major barrier for many patients. With Awiqli:
- Only 1 injection per week
- Reduced injection burden
- Improved patient compliance
2. More Stable Glucose Levels
Due to its pharmacokinetics:
- Provides steady basal insulin coverage
- Reduces day-to-day variability
- May lower risk of missed doses
3. Simplified Diabetes Management
For both physicians and patients:
- Easier titration schedule
- Less frequent dose adjustments
- Potential for improved long-term outcomes
Awiqli FlexTouch Pen: Formulation and Strength
Awiqli is available in a FlexTouch insulin pen with the following specifications:
- Pen volume: 3 mL
- Concentration: 700 units/mL
- Total insulin per pen: 2100 units
- Maximum dose per injection: 700 units
- Dose increments: 10 units
This high-concentration formulation is specifically designed to deliver a full week’s insulin in a single injection.
How to Start Awiqli: Dosing Guidelines
1. Insulin-Naïve Patients
For patients starting insulin therapy:
- Starting dose: 70 units once weekly
This provides a simple and standardized initiation strategy.
2. Patients Already on Daily Insulin
Week 1 (Transition Phase)
- Dose = 1.5 × total daily insulin dose × 7
- Round to the nearest 10 units
👉 This higher initial dose compensates for the pharmacokinetic differences during transition.
Week 2 and Beyond
- Dose = daily insulin dose × 7
This reflects the patient’s usual weekly insulin requirement.
Example Calculation
If a patient is taking 40 units/day of basal insulin:
- Week 1:
1.5 × 40 × 7 = 420 units → round to 420 units - Week 2 onward:
40 × 7 = 280 units
Mechanism of Action
Like other basal insulins, insulin icodec works by:
- Enhancing glucose uptake in muscles and fat
- Suppressing hepatic glucose production
- Maintaining baseline insulin levels throughout the week
Its unique molecular design allows slow and continuous release, enabling once-weekly dosing.
Side Effects of Awiqli
The safety profile of Awiqli is similar to other insulin therapies, including:
- Hypoglycemia (most common)
- Injection site reactions
- Weight gain
- Lipodystrophy (rare with proper rotation)
As with all insulin therapies, careful dose titration and monitoring are essential.
Who Should Consider Awiqli?
Awiqli may be particularly beneficial for:
- Patients struggling with daily insulin adherence
- Individuals with busy lifestyles
- Patients requiring simplified regimens
- Those already on basal insulin looking for convenience
However, it should always be prescribed under medical supervision.
Clinical Impact: What This Means for Diabetes Care
The approval of insulin icodec signals a broader shift toward:
- Patient-friendly therapies
- Reduced treatment burden
- Improved long-term adherence
It aligns with trends seen in other weekly therapies, such as GLP-1 receptor agonists, reinforcing the move toward less frequent dosing without compromising efficacy.
Awiqli Insulin Price Per Pen:
The cost of Awiqli (insulin icodec) varies across regions, reflecting differences in healthcare systems, insurance coverage, and local pricing regulations.
In the United States and Canada, the expected price is approximately USD 98.9 per pen, although the final out-of-pocket cost for patients may differ depending on insurance plans and pharmacy pricing.
In other countries, prices may be lower or higher based on government subsidies, import policies, and market availability.
As with most newer insulin analogs, initial pricing tends to be higher, but broader adoption and competition may gradually influence affordability over time
Final Thoughts
Awiqli (insulin icodec) is not just another insulin—it’s a paradigm shift in diabetes management.
By reducing injections from 365 per year to just 52, it has the potential to significantly improve adherence, patient satisfaction, and ultimately, glycemic outcomes.
For clinicians like you who focus on lifestyle-based and patient-centered care, this innovation offers a powerful new tool to simplify diabetes treatment without compromising effectiveness.
